West Receives Exhibitor Award at INTERPHEX 2022 for Proprietary DeltaCube™ Modeling Platform
West Pharmaceutical Services (NYSE: WST) has been awarded the Biotech Innovation Award for its DeltaCube™ Modeling Platform at INTERPHEX 2022 in New York. This platform aids in container closure system (CCS) selection, optimizing drug development processes. Senior VP Chris Ryan emphasized its role in reducing risk and accelerating drug delivery to patients. The DeltaCube™ platform leverages over 90 years of experience to enhance vial integrity and troubleshoot defects efficiently. In 2021, West generated $2.83 billion in net sales, underscoring its position in the market.
- Award recognition for DeltaCube™ Modeling Platform underscores its innovation and industry relevance.
- DeltaCube™ enhances drug development efficiency by supporting early-stage CCS selection.
- Utilization of over 90 years of expertise in CCS and container closure integrity adds credibility.
- None.
The DeltaCube™ Modeling Platform is an analytics platform aimed at container closure system (CCS) selection, optimization, and usage
EXTON, Pa., May 24, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced it received the Biotech Innovation Award for the DeltaCube™ Modeling Platform at the INTERPHEX 2022 Technical Conference in New York City.
"West is honored to receive an INTERPHEX 2022 Exhibitor Award recognizing the innovation of our DeltaCube™ Modeling Platform," said Chris Ryan, Senior Vice President, Containment and Glass Systems. "By supporting drug development and addressing containment earlier in the process, we can ensure needed drugs get safely to patients quicker. This tool provides a solution for the industry to reduce risk and accelerate development during the early-stage vial container closure system (CCS) selection and usage."
The DeltaCube™ Modeling Platform, a secure online vial integrity software modeling platform designed to help developers make more confident decisions about their container closure systems (CCS), uses a big-data approach, built on 90-plus years of CCS and container closure integrity (CCI) experience. The DeltaCube™ modeling platform provides an efficient and cost-effective tool to guide vial, stopper and seal combination selection based on fit, and supports the troubleshooting of defects or CCI failures due to component dimensional issues.
For more information about West, please visit our website: www.westpharma.com. To learn more about DeltaCube, click here.
For more information about INTERPHEX 2022 and the Exhibitor Award, please visit INTERPHEX's Exhibitor Awards website: www.interphex.com/en-us/exhibit/exhibitor-awards.html.
Forward-Looking Statements
Certain forward-looking statements are included in this press release. They use words such as "ensure," "reduce," "accelerate," and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. Specifically, there is no certainty that the DeltaCube™ Modeling Platform will achieve any particular result. These forward-looking statements involve a number of risks and uncertainties. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: customer decisions to move forward with our new products and product categories; dependence on third-party suppliers and partners; and the ability to meet development milestones with key customers. These important factors are not all inclusive. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2021. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year.
Headquartered in Exton, Pennsylvania, and in business for nearly a century, West in its fiscal year 2021 generated
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
View original content to download multimedia:https://www.prnewswire.com/news-releases/west-receives-exhibitor-award-at-interphex-2022-for-proprietary-deltacube-modeling-platform-301554271.html
SOURCE West Pharmaceutical Services, Inc.
FAQ
What award did West Pharmaceutical Services win at INTERPHEX 2022?
How does the DeltaCube™ Modeling Platform benefit drug developers?
What was West Pharmaceutical Services' revenue in 2021?
Where is West Pharmaceutical Services headquartered?
What is the significance of the DeltaCube™ Modeling Platform in the pharmaceutical industry?
